Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company. It develops products and technology to improve the lives of transplant patients. The firm’s products and technology include Envarsus XR and meltdose technology. Veloxis was acquired by Asahi Kasei for $1.3 billion in 2019.